FRANKLIN LAKES, N.J., June 23, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from ...

The conventional management of treatment-resistant, recurrent malignant ascites involves repeated large-volume paracentesis (needle drainage of fluid) procedures that are carried out in hospital. Most ...

The PeritX Peritoneal Catheter System allows patients with either malignant or nonmalignant ascites to drain the built-up fluids from their abdomen in the comfort of their own home, rather than making ...

Validation of urinary HE4 as a biomarker for ovarian cancer. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text component.

Becton, Dickinson and Company BDX, popularly known as BD, recently announced receipt of the FDA’s 510(k) clearance for its PeritX Peritoneal Catheter System. The system is to be used for the drainage ...

Pleural Dynamics, an early-stage medical device startup developing solutions for the management of chronic, recurrent effusions and refractory ascites, has received FDA 510(k) clearance for its ...

Malignant ascites represent one of the most challenging complications of advanced intra-abdominal and gynaecological malignancies worldwide, imposing a profound impact on patient comfort, mobility and ...

Cell-free and concentrated ascites reinfusion therapy (CART) is frequently used to treat refractory ascites in Japan. However, its efficacy remains unclear. This controlled cohort study verified the ...

Malignant ascites can develop with late stage pancreatic cancer. Ascites involves the buildup of fluid in the abdomen. Doctors can drain the fluid to relieve symptoms, but fluid may return. Ascites ...

You may send us your comments on this form by clicking the button below. You will first be asked to supply your name, email address, and location. You must then acknowledge our data protection ...